The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Apr. 11, 8:00 PM

Slide #3. Crinetics Pharmaceuticals, Inc. Secondary Offering

Company: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Date announced: 4/7/2021
Shares Offered: 4,562,044
Date of Pricing: 4/7/2021
Price Per Share: $16.44
Secondary Offering Details: Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing conditions.

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. CRN00808, Co.'s main product candidate, establishes a class of oral selective nonpeptide somatostatin receptor type 2 (sst2) biased agonists designed for the treatment of acromegaly. CRN0194 is an oral nonpeptide sst2 biased agonist for the treatment of neuroendocrine tumors that originate from neuroendocrine cells commonly found in the gut, lung or pancreas. Co. develops a class of oral selective nonpeptide somatostatin type 5 receptor agonists designed to treat congenital hyperinsulinism.

CRNX SEC Filing Email Alerts Service

Open the CRNX Page at The Online Investor »

Company Name: 
Crinetics Pharmaceuticals Inc
Website: 
www.crinetics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding CRNX: 
21
Total Market Value Held by ETFs: 
$42.83M
Total Market Capitalization: 
$543.00M
% of Market Cap. Held by ETFs: 
7.89%
 

Open the CRNX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
63rd percentile
(ranked higher than approx. 63% of all stocks covered)

Analysts' Target Price:
CRNX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.